【产品介绍】：

生物活性：Dovitinib-d8 is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Dovitinib-d8 相关抗体:
FGFR2/CD332 Antibody
c-Kit Antibody (YA502)
Phospho-PDGFR beta (Y740) Antibody
VEGF Receptor 2 Antibody (YA014)
FGFR1 Antibody
FGFR1 Oncogene Partner Antibody
FGFR2 Antibody
FGFR3 Antibody
PDGFR alpha Antibody
FGF2 Antibody
M-CSF Antibody
VEGF Receptor 1 Antibody
VEGFA Antibody
CSF-1R Antibody (YA1299)
VEGF Receptor2 Antibody
FGF1 Antibody (YA1430)
PDGF B Antibody (YA1556)
FGFR4 Antibody (YA1588)
PLGF Antibody (YA1812)
PDGFR beta Antibody (YA1925)
VEGFD Antibody (YA2385)
FGF19 Antibody (YA2672)
TACC3 Antibody (YA2921)
Phospho-PDGFR beta (Tyr740) Antibody (YA3062)
FGF21 Antibody (YA3276)
G-CSF Antibody (YA3307)
c-Kit Antibody
SCF Antibody
PGF Antibody (YA1434)
Neuropilin 1 Antibody (YA1831)
分子量：400.48
Formula：C21H13D8FN6O
CAS 号：1246819-84-0
非标记 CAS：405169-16-6
中文名称：多韦替尼 d8
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (530 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Cox L, et al. Levomepromazine for nausea and vomiting in palliative care. Cochrane Database Syst Rev. 2015;2015(11):CD009420. Published 2015 Nov 2.
 [Content Brief]
[2]. Trudel S, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005, 105(7), 2941-2948.
 [Content Brief]
[3]. Huynh H, et al. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol. 2012, 56(3), 595-601.
 [Content Brief]
[4]. Lee Y, et al. A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro. Mol Cells. 2016 May 31;39(5):389-94
 [Content Brief]
[5]. Chon HJ, et al. Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells. Amino Acids. 2016 Jul;48(7):1591-9.
 [Content Brief]